Granted U.S. Patent from PTSD Discovery Programme

AI SummaryClose X

Solvonis Therapeutics plc has been granted a second U.S. patent, U.S. Patent No. 12,595,269, covering a new series of monoamine modulator compounds from its post-traumatic stress disorder (PTSD) discovery program, with patent protection expected until February 2043. This composition-of-matter patent, which protects the compounds themselves, reinforces the breadth of the company's research platform and strengthens its intellectual property estate in the PTSD therapeutic area, complementing recent milestones including the selection of SVN-114 as a lead candidate and the grant of a prior U.S. patent. The company highlights the growing strategic interest in next-generation psychiatric treatments, referencing Otsuka Pharmaceutical's potential $1.225 billion acquisition of Transcend Therapeutics.

Disclaimer*

UK 100

Latest directors dealings